Overview

A Study of RO5185426 in Patients With Metastatic Melanoma

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche